However, despite the high expression of TOP2A, advanced MPNST patients do not respond well to doxorubicin given a 2 year overall survival rate of approximately 20%, which is roughly equivalent to the outcome of patients with metastatic STS other than MPNST [7]. This evidence concerns the gene TOP2A and malignant peripheral nerve sheath tumor.